Prostate cancer | GlobalPost

FDA approves Bayer Pharmaceuticals drug for prostate cancer that has spread to the bones

The Canadian PressMay 15, 2013 13:15

WASHINGTON - The Food and Drug Administration has approved a new injectable drug that uses radiation to treat advanced prostate cancer that has spread to the bones. The FDA said Wednesday it approved the drug, Xofigo from Bayer Pharmaceuticals, for men whose cancer has grown into bone tumors even after receiving medication or surgery to lower testosterone. The hormone spurs growth of prostate tumors. More than 238,000 U.S. men will be diagnosed with prostate cancer this year and 29,720 will die from the disease, according to the National Cancer Institute.

ANALYSIS-In war against cancer, progress is in the eye of the beholder

Thomson ReutersJanuary 8, 2013 09:56

* Deaths rates fell an average 1.5 percent per year, 2000 to 2009 * In men, mortality rose for melanoma, cancers of liver and pancreas * Much of improvement in incidence, mortality reflects less smoking By Sharon Begley NEW YORK, Jan 7 (Reuters) - As the United States enters the fifth decade of its "war on cancer," deaths continue to decline, according to an exhaustive report based on official data released on Monday.